Orient Pharma Co., Ltd.(TW:4166)
NT$22.55+0.05 (+0.22%)
TW:4166
Orient Pharma Co., Ltd. financials statements
NT$22.55
At close:+0.05 (+0.22%)
Orient Pharma Co., Ltd. (4166) Ratios
Orient Pharma Co., Ltd. Ratios
TW:4166's free cash flow for Q2 2026 was NT$21.97M. For the 2026 fiscal year, TW:4166's free cash flow was decreased by NT$-30.75M and operating cash flow was NT$52.72M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 6.73 | 1.49 | 1.10 | 1.21 | 1.05 |
| Quick Ratio | 5.01 | 0.92 | 0.69 | 0.65 | 0.67 |
| Cash Ratio | 3.14 | 0.17 | 0.15 | 0.22 | 0.31 |
| Solvency Ratio | 0.92 | 0.33 | 0.18 | 0.05 | -0.06 |
| Operating Cash Flow Ratio | 1.92 | 0.40 | -0.18 | 0.03 | -0.13 |
| Short-Term Operating Cash Flow Coverage | 16369.68 | 0.68 | -0.27 | 0.12 | -0.29 |
| Net Current Asset Value | NT$ 884.26M | NT$ -4.57M | NT$ -269.93M | NT$ -334.53M | NT$ -208.59M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.07 | 0.22 | 0.28 | 0.28 | 0.24 |
| Debt-to-Equity Ratio | 0.08 | 0.31 | 0.43 | 0.47 | 0.37 |
| Debt-to-Capital Ratio | 0.07 | 0.23 | 0.30 | 0.32 | 0.27 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.02 | 0.06 | 0.14 | 0.09 |
| Financial Leverage Ratio | 1.15 | 1.41 | 1.53 | 1.70 | 1.58 |
| Debt Service Coverage Ratio | 45.45 | 0.84 | 0.44 | 0.48 | -0.17 |
| Interest Coverage Ratio | 33.01 | 11.31 | 2.00 | -4.57 | -18.31 |
| Debt to Market Cap | 0.00 | 0.04 | 0.11 | 0.07 | 0.09 |
| Interest Debt Per Share | 0.88 | 2.51 | 3.28 | 2.76 | 2.25 |
| Net Debt to EBITDA | -0.99 | 1.48 | 3.68 | 12.21 | -7.25 |
| Profitability Margins | |||||
| Gross Profit Margin | 50.48% | 53.28% | 52.66% | 30.35% | 30.79% |
| EBIT Margin | 18.64% | 14.48% | 4.14% | -6.59% | -22.53% |
| EBITDA Margin | 28.33% | 25.58% | 19.37% | 6.91% | -8.46% |
| Operating Profit Margin | 18.64% | 12.91% | 3.12% | -6.59% | -22.53% |
| Pretax Profit Margin | 17.47% | 13.34% | 2.58% | -8.03% | -23.76% |
| Net Profit Margin | 14.88% | 8.78% | 2.50% | -5.62% | -22.15% |
| Continuous Operations Profit Margin | 14.88% | 8.78% | 2.50% | -5.62% | -22.15% |
| Net Income Per EBT | 85.20% | 65.82% | 97.23% | 69.96% | 93.24% |
| EBT Per EBIT | 93.71% | 103.30% | 82.60% | 121.86% | 105.46% |
| Return on Assets (ROA) | 7.09% | 4.26% | 0.87% | -1.56% | -5.82% |
| Return on Equity (ROE) | 8.13% | 6.01% | 1.33% | -2.64% | -9.20% |
| Return on Capital Employed (ROCE) | 9.49% | 7.77% | 1.39% | -2.25% | -7.77% |
| Return on Invested Capital (ROIC) | 8.04% | 4.44% | 1.13% | -1.47% | -6.33% |
| Return on Tangible Assets | 8.26% | 5.24% | 1.10% | -1.57% | -5.87% |
| Earnings Yield | 3.44% | 1.34% | 0.49% | -0.74% | -2.97% |
| Efficiency Ratios | |||||
| Receivables Turnover | 5.29 | 4.24 | 4.75 | 6.22 | 7.34 |
| Payables Turnover | 11.18 | 15.94 | 7.58 | 5.76 | 16.64 |
| Inventory Turnover | 2.15 | 2.04 | 1.80 | 1.84 | 2.04 |
| Fixed Asset Turnover | 1.60 | 1.35 | 0.94 | 0.53 | 0.53 |
| Asset Turnover | 0.48 | 0.49 | 0.35 | 0.28 | 0.26 |
| Working Capital Turnover Ratio | 2.13 | 8.15 | 13.59 | 11.14 | 4.56 |
| Cash Conversion Cycle | 206.07 | 241.79 | 231.49 | 194.10 | 206.33 |
| Days of Sales Outstanding | 69.04 | 86.08 | 76.89 | 58.69 | 49.70 |
| Days of Inventory Outstanding | 169.69 | 178.62 | 202.73 | 198.80 | 178.57 |
| Days of Payables Outstanding | 32.66 | 22.90 | 48.13 | 63.39 | 21.94 |
| Operating Cycle | 238.73 | 264.70 | 279.62 | 257.49 | 228.27 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.55 | 0.88 | -0.46 | 0.06 | -0.29 |
| Free Cash Flow Per Share | 1.40 | 0.76 | -0.79 | -0.09 | -0.66 |
| Dividend Paid and CapEx Coverage Ratio | 10.05 | 7.19 | -1.40 | 0.39 | -0.77 |
| Capital Expenditure Coverage Ratio | 10.05 | 7.19 | -1.40 | 0.39 | -0.77 |
| Operating Cash Flow Coverage Ratio | 1.84 | 0.36 | -0.14 | 0.02 | -0.13 |
| Operating Cash Flow to Sales Ratio | 0.26 | 0.16 | -0.12 | 0.02 | -0.12 |
| Free Cash Flow Yield | 5.36% | 2.11% | -3.92% | -0.45% | -3.57% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 29.06 | 75.00 | 202.20 | -139.00 | -33.64 |
| Price-to-Sales (P/S) Ratio | 4.32 | 6.57 | 5.06 | 7.62 | 7.47 |
| Price-to-Book (P/B) Ratio | 2.36 | 4.49 | 2.70 | 3.58 | 3.10 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 18.67 | 47.34 | -25.52 | -222.34 | -28.00 |
| Price-to-Operating Cash Flow Ratio | 16.82 | 40.75 | -43.74 | 342.50 | -64.59 |
| Price-to-Earnings Growth (PEG) Ratio | 0.33 | 0.20 | -1.21 | 1.91 | 0.74 |
| Enterprise Value Multiple | 14.28 | 27.15 | 29.81 | 122.45 | -95.48 |
| Enterprise Value | 5.66B | 8.49B | 5.14B | 4.33B | 3.74B |
| EV to EBITDA | 14.28 | 27.15 | 29.81 | 122.45 | -95.48 |
| EV to Sales | 4.05 | 6.94 | 5.77 | 8.46 | 8.08 |
| EV to Free Cash Flow | 17.47 | 50.07 | -29.11 | -246.97 | -30.30 |
| EV to Operating Cash Flow | 15.73 | 43.10 | -49.90 | 380.43 | -69.90 |
| Tangible Book Value Per Share | 9.28 | 5.90 | 5.10 | 5.76 | 5.89 |
| Shareholders’ Equity Per Share | 11.07 | 8.01 | 7.49 | 5.83 | 5.97 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.15 | 0.34 | 0.03 | 0.30 | 0.07 |
| Revenue Per Share | 6.05 | 5.48 | 3.99 | 2.74 | 2.48 |
| Net Income Per Share | 0.90 | 0.48 | 0.10 | -0.15 | -0.55 |
| Tax Burden | 0.85 | 0.66 | 0.97 | 0.70 | 0.93 |
| Interest Burden | 0.94 | 0.92 | 0.62 | 1.22 | 1.05 |
| Research & Development to Revenue | 0.06 | 0.08 | 0.11 | 0.25 | 0.47 |
| SG&A to Revenue | 0.32 | 0.31 | 0.38 | 0.13 | 0.12 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.73 | 1.21 | -4.62 | -0.28 | 0.49 |
Currency in TWD
